
    
      The clinical study will include 2 parts. Part 1 will estimate the MTD in dose escalation
      cohorts in patients with advanced solid tumors for whom no standard therapy is available in
      order to establish the RP2D. Part 2 will include patients with previously treated metastatic
      triple negative breast cancer (TNBC).
    
  